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1 Introduction 
Health Technology Assessment/HTA has in many countries become an inte-
gral part of health policy decision-making: the collection and synthesis of ev-
idence is a research-based, objective activity with the intention to provide the 
scientific basis for decisions for efficient and appropriate use of resources [1]. 
HTA is based on a stringent methodology giving special importance to the 
traceability of the results and to equi-distance to interest groups in order to 
avoid undue influence.1 
In some, but not all instances scientific evidence of sufficiently high quality 
that can directly lead to clear-cut policy decisions is lacking [2]. In addition 
uncertainty and social values need to be addressed [3]. As a result the need 
for an additional value based activity, for a “reality check” of evidence arises. 
Contextualizing the evidence and framing recommendations is carried out in 
an appraisal of the evidence that was before synthesized during the assess-
ment step [1]. 
The figure below illustrates the knowledge value chain in the health care 
sector and highlights the domains covered by HTA as well as the multistep 
process from assessment to appraisal and to health policy decision-making. 
These steps however are not distinct from each other: There will often be in-
teraction between the steps of assessment, appraisal and decision-making, 
e.g. the framing of research questions may already be driven by interests. 
 
Figure 1: Knowledge value chain in the health sector. Source: developed from Garrido (2008)[4] 
Abbreviation: HTA ... Health Technology Assessment 
The focus of this report is on the process and the guiding principles of ap-
praising evidence. There is not one „right“ way to appraise evidence. An ap-
praisal committee – sometimes also called policy committee – acts like a ju-
ry: a jury must above all be seen as credible and respected by those affected 
by the recommendations. The term jury underlines the subjective nature of 
formulating recommendations. Experts making up an appraisal committee 
should therefore demonstrably bring multiple perspectives to the table, they 
should be fair and unbiased, using a transparent process [1].  
                                                             
1 http://hta.lbg.ac.at/page/about-us 
assessment  
= collection and 
synthesis of evidence 
= method with focus on 
traceability/replicability 
of the results  
appraisal = 
contextualizing 
evidence and 
formulation of 
recommendations 
multistep process: 
assessment – appraisal  
– decision-making 
focus of this report is  
on process and guiding 
principles of appraising 
evidence 
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This design distinguishes appraisal committees from mono-discipline and in-
terest-driven expert committees (eminence-based) deciding on their recom-
mendations behind closed doors. It also gives appraisal committees a role 
that is different from merely consulting stakeholders. 
Historically HTA evolved somewhat distant from the complexities of real 
world health systems’ needs. Often policy makers are navigating between 
competing needs, political imperatives, patient and professional preferences 
on the micro level, the societal macro-perspective and the reality of fiscal con-
straints. Policy makers have therefore at times not found HTA alone relevant 
to their needs [2]. Appraisal committees operate at this complex interface 
between science and policy, where many mistakes and misunderstandings lie 
in wait. An appraisal committee discussing the potential impact of health 
technologies from various perspectives, taking into account various interests 
and tasked with drawing up contextualized and applicable recommendations 
is one way to bridge the divide between ivory tower HTA and policy making 
[5] and for research to better inform public services. An appraisal committee 
can make the life of policy makers easier. It can first serve to translate policy 
issues into research questions (which is not the focus of this working paper), 
and then help ‘digest’ and “translate” results and present them to policymak-
ers in a concise way. Typically the appraisal committee will draw different 
scenarios and provide arguments and counter-arguments. Appraisal commit-
tees, however, do NOT replace those who are politically accountable. Another 
important aspect when assessing and appraising evidence is the factor time. 
Timeliness is almost always paramount in the policy world. Some pragmatic 
trade-off in favor of timeliness at the expense of depth of analysis is there-
fore suggested [6]. 
In the following chapter examples for (good) practice of appraisal commit-
tees supporting decisions in different sectors of the health care system (e.g. 
centralized screening or technology uptake decisions; regional hospitals in-
vestment decisions etc.) from the United Kingdom, Canada, the Netherlands, 
the United States, Australia, Switzerland and Germany are presented. Chap-
ter 3 presents a Canadian (good) practice example from Ontario in more de-
tail. The final chapter 4 distills possible lessons from the international expe-
rience into seven recommendations. 
An initial hand search of institutional websites for procedural descriptions of 
the work of appraisal committees yielded only little officially published ma-
terial. Experts known to the authors from professional networks were contact-
ed next and asked to provide further information. Hence the resulting here 
presented selection of 11 appraisal committees is selective, the underlying 
materials are by no means comprehensive. 
 
 
 
appraisal committee ≠ 
clinical expert group ≠ 
stakeholder panel 
policy makers navigate 
between competing 
needs, political 
imperatives, patient  
and professional 
preferences, a societal 
macro perspective and 
fiscal constraints 
 
appraisal committees 
“digest” and “translate” 
research results ... 
 
... draw up different 
scenarios ... 
 
thereby making the life 
of policy decision takers 
easier 
(good) practice 
examples of assessing 
evidence ... 
from different sectors  
of health care system ... 
distilled into  
7 recommendations 
method:  
web search, experts 
contacted through 
professional networks, 
resulting overview not 
comprehensive 
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2 Appraisal committees internationally 
In this chapter information on the following 11 appraisal committees from 7 
countries is presented.  
 United Kingdom (England): Technology Appraisal Committee: 
Advisory Committee to the Board of the National Institute for Health 
and Clinical Excellence (NICE) 
 United Kingdom (England): National Screening Committee  
(UK NSC): Advisory Committee to the Ministry of Health and the 
National Health Service 
 United Kingdom (Scotland): Scottish Intercollegiate Guidelines 
Network (SIGN) for National Health Service (NHS) Scotland 
 Canada (Ontario): Ontario Health Technology Advisory Committee 
(OHTAC) for Health Quality Ontario 
 Canada (Quebec): Policy Committee of McGill University Health 
Centre – Technology Assessment Unit 
 The Netherlands: Appraisal Committee at the National Health Care 
Institute – Zorginstituut Nederland (ZIN) and The Health Council of 
the Netherlands – De Gezondheidsraad (GR) – Advisory Committee to 
the Ministry of Health 
 Unites States of America: United States Preventive Services Task 
Force (USPSTF) 
 Australia: National Health and Medical Research Council (NHMRC) 
inter alia approves guidelines, responsible to the Ministry of Health 
 Switzerland: Swiss Federal Services Policy Commission – Eidgenössische 
Kommission für allgemeine Leistungen und Grundsatzfragen (ELGK), 
Advisory Committee to Ministry of Interior, incorporating the Federal 
Office of Public Health – Eidgenössisches Departement des Innern/ 
Bundesamt für Gesundheit 
 Germany: Subcommittee – themenbezogene Arbeitsgruppe – appraises 
evidence for the Federal Joint Committee – Gemeinsamer 
Bundesausschuss (G-BA) 
Not all of the presented committees officially call themselves “Appraisal Com-
mittee”. All are, though, juries of evidence, putting systematically synthesized 
evidence into a political context. In this chapter information on committee 
remit/terms of reference, on the composition of committee membership, on 
the appraisal criteria used and on the rules for the process of appraising evi-
dence is presented. 
 
Remit/terms of refercence 
The remit/terms of reference of the presented appraisal committees vary, as 
does their respective statutory nature and the financial resources at their dis-
position. Both Germany’s G-BA – advised by the relevant subcommittee – and 
Switzerland’s ELGK have a direct say in the determination of social insurance 
coverage of a service. The Scottish Intercollegiate Guidelines Network SIGN, 
as the name suggests, draws up national treatment guidelines. The hospital-
based HTA produced by the Technology Assessment Unit of McGill Univer-
sity Health Centre in Canada is appraised by their Policy Committee in light 
of the needs of this individual tertiary hospital. While the appraisal of HTA 
11 appraisal committees 
from 7 countries: 
UK: NICE+ UK NSC + 
SIGN 
CA: OHTAC + McGill 
NL: ZIN + GR 
USA: USPSTF 
AU: NHMRC 
CH: ELGK 
GER: G-BA 
appraisal committees 
are “juries of evidence”: 
putting the available 
evidence into context  
depending on  
statutory nature:  
 
binding or non-binding 
recommendations 
 
support to local, 
regional or national 
decision-making 
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is only a small part of what Australia’s National Health and Medical Research 
Council NHMRC does, the United States Preventive Services Task Force US-
PSTF deals exclusively with evidence appraisal, confined to preventive services.  
 
Composition 
The size of membership lies between 9 in the Netherland’s Health Council 
and 39 in Scotland’s SIGN. Representing a professional body or a wider pub-
lic constituency forms the basis for nominations of individual members: Pro-
fessional groups (clinicians and other health care providers), academics 
(from different disciplines: public health, economics, ethics, social sciences 
etc.) and administrators (managers, payers), government representatives, lay 
members (citizens, insurees, patients) and, like in the case of Germany’s G-
BA, corporatist representatives (physicians, hospitals, sickness funds) or, in 
UK’s NICE, representatives from industry make up these diverse bodies. 
Sometimes a set of members are only observers and have no voting right (e.g. 
UK’s NSC). Limits on the duration of an appointment are sometimes in place 
(e.g. Ontario’s OHTAC for Chair and Vice-Chair). All committees put a list 
with the names and affiliations of their members online. (In Germany only 
the names of the members of the G-BA plenum are published, names and 
positions of sub-committee members are confidential.) 
 
Appraisal criteria 
Many, though not all, committees lay down transparent appraisal criteria in 
considerable detail (e.g. Ontario’s OHTAC, UK’s NSC, Netherland’s National 
Health Care Institute). The Appendix presents two sets of appraisal criteria 
in detail. Sometimes criteria are general in nature (Germany’s G-BA), some 
committees strive towards operationalization (Switzerland’s ELGK). How cri-
teria are weighted against each other is only rarely addressed explicitly, and 
if, like at US PSTF, only cursory. 
 
Process of appraising evidence 
All bodies require a declaration of conflicts of interests (CoI). Some bodies 
make the declaration of interest of each member publicly available (e.g. UK’s 
NICE, Health Council of the Netherlands [7], Switzerland’s ELGK). Infor-
mation on how appraisal committees deal with explicit CoI (e.g. NICE or US-
PSTF exclusion from voting for a particular recommendation) is more rarely 
available. Many committees post their agenda and minutes online (e.g. UK’s 
NICE, UK’s NSC, Australia’s NHMRC). Some committees have a long tradi-
tion of involving the wider public in the deliberative process (e.g. UK’s NICE), 
most have a policy for that and for systematically dealing with comments in 
place (e.g. Scotland’s SIGN). Some committees put a particular emphasis on 
distributional effects of recommendations (e.g. Australia’s NHMRC). Some ap-
praisal processes allow for appeal (e.g. UK’s NICE), some don’t (Switzerland’s 
ELGK). Procedural arrangements for some appraisal committees include fol-
lowing-up on how the addressee of the recommendations dealt with them, e.g. 
Health Council of the Netherlands [7]. There, following every report, the min-
ister of health officially briefs parliament on her/his actions taken or not. This 
is also published online. Some appraisal committees evaluate their own im-
pact: e.g. Ontario’s OHTAC focuses on assuring ongoing relevance, on quali-
ty and on improving overall performance in its periodic self-evaluations. 
The table below offers more detailed information in these four areas. 
individuals nominated 
as representatives of 
professional bodies and 
the narrower and wider 
public 
 
broad range of size:  
9-39 members 
 
public access to 
information 
criteria most often: 
general in nature,  
rarely operationalized 
(transparent) policies or 
procedures to deal with: 
 
public availability of 
conflict of interest, 
involvement of public, 
processing of comments,  
documentation of 
consensus and dissent, 
reasons for deviating 
from evidence, 
dissemination of 
recommendations, 
possibility of appeal, 
impact evaluation 
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Table 5.1-1: Examples of appraisal committee practice 
Country 
Organization/ 
Source of 
Information 
Remit/ 
Terms of Reference Composition Appraisal Criteria Process 
UK National 
Institute for 
Health and 
Clinical 
Excellence 
NICE 
www.nice.org.uk 
 Technology Appraisals 
Committee operates as a 
standing Advisory Committee 
of the Board of NICE 
 It receives, considers and 
interprets evidence on the 
clinical effectiveness and cost 
effectiveness of health 
technologies referred to it 
 It develops guidance for the 
National Health System NHS 
in accordance with the 
published methods and 
processes of Health 
Technology Appraisal 
 It submits its recommendations 
to NICE’s Guidance Executive, 
which acts under delegated 
powers of the Board in 
considering and approving the 
guidance for publication 
Technology Appraisal Committee 
divided into four branch committees 
(A-D) 
 Chair and members appointed for a 
period of 3 years, extension up to  
10 years 
 Drawn from 
 National Health Service NHS 
 Patient and carer organizations 
 Academia 
 Pharmaceutical and medical 
devices industries 
Committee A currently has 31 members. 
List of members available online 
NICE publishes a detailed guide to 
the methods of technology appraisal 
(available at: 
www.nice.org.uk/article/PMG9/ 
chapter/Foreword) 
Broad criteria: 
 The broad balance between the 
benefits and costs of providing 
health services or social care 
 The degree of need of people for 
health services or social care 
 The desirability of promoting 
innovation in providing health 
services or social care 
Narrower criteria: 
 clinical effectiveness and health-
related factors  
 appropriateness and relevance of 
comparator technologies 
 cost effectiveness 
 non-health factors 
 impact on broader social 
considerations 
 costs/savings/benefits outside 
the health sector 
 Monthly meetings 
 Attendance of at least 50% of 
meetings mandated 
 Open to public and press 
 Agenda published online at least  
20 working days prior 
 Decisions normally by consensus of 
members present 
 Anonymous voting 
 Simple majority 
 Principle of collective responsibility: 
no speaking out against 
recommendations in public 
 Petitions to be made formally to 
secretariat, not directly to Committee 
or to individual members 
Structure of the meeting: 
 Part 1 (public session) 
 Members of the Committee and 
individuals having direct input into 
the discussions (including clinical 
specialists, commissioning experts, 
patient experts and NICE staff) 
declare their interests, which are 
recorded in the minutes 
 Part 2 (closed session) 
 During the closed session, the 
Committee considers ‘commercial in 
confidence’ information and agrees 
on the recommendations. Members 
of the public and press are asked to 
leave the meeting before this 
discussion takes place 
 Unconfirmed minutes online within 
15 working days 
 Confirmed minutes online within  
6 weeks 
Consultee organizations (right of 
appeal against final recommendations) 
 National groups representing 
patients and carers 
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Country 
Organization/ 
Source of 
Information 
Remit/ 
Terms of Reference Composition Appraisal Criteria Process 
 Bodies representing health 
professionals 
 Manufacturer(s) or sponsor(s)  
of the technology in development 
 Department of Health 
 Primary care trusts and local health 
boards 
Commentator organizations  
(no right of appeal against final 
recommendations) 
 Manufacturers of comparator 
technologies 
 Research groups working in the area 
UK UK National 
Screening 
Committee 
UK NSC 
www.screening.
nhs.uk 
 It advises ministers and the 
National Health System NHS 
about: 
 The case for implementing 
new population screening 
programs not presently 
provided by the NHS 
 Screening technologies of 
proven effectiveness but 
which require controlled 
and well-managed 
introduction 
 The case for continuing, 
modifying or withdrawing 
existing population 
screening programs. In 
particular, programs 
inadequately evaluated or 
of doubtful effectiveness, 
quality, or value 
 Generic issues relating to 
screening programs and policy 
 It calls on sound evidence to 
inform its advice and 
recommendations 
 It agrees standards for the new 
programs, which can be used 
as a basis for discussion by the 
standard setting bodies 
 It advises on their 
implementation in the NHS 
Advisory Committee 
Currently 19 Members 
 Deputy Chief Medical Officer, 
England (Chair) 
 2 General practitioners 
 3 Hospital physicians 
 Obstetrician 
 Community Child Health 
 Genetics 
 1 Consumer Representative 
 2 User Representatives 
 2 Academia 
 School of Law, King's College 
London 
 Health Economics Research 
Group, Brunel University 
 1 Department of Health, Social Services 
and Public Safety Northern Ireland 
 1 Scottish Government 
 1 Welsh Government 
 1 Joint Director of Public Health, 
National Health Service Borders 
 1 Public Health Agency Northern 
Ireland 
 1 Screening Division, Public Health 
Wales 
 1 UK National Screening Committee 
 1 UK NSC Screening Programs Director 
22 program appraisal criteria [8],  
see Appendix 
 3 meetings per year 
 Draft minutes and summary of key 
decisions published 4 weeks later 
 Recommendations first to ministers 
before sharing them more widely 
3 month consultation period for 
evidence report 
 Pre-defined criteria for who qualifies 
as stakeholder: comments by others 
„considered more circumspectly“ 
 Incorporation of stakeholder views 
 If particularly controversial: 
stakeholder workshop 
 Public availability for comment on 
website 
UK NSC’s role, terms of reference and 
membership are reviewed every three 
years 
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Country 
Organization/ 
Source of 
Information 
Remit/ 
Terms of Reference Composition Appraisal Criteria Process 
Observers 
 National Cancer Screening Service, 
Republic of Ireland 
 National Coordinating Centre for HTA 
 Medical Research Council 
List of members available online 
UK Scottish 
Intercollegiate 
Guidelines 
Network 
SIGN 
www.sign.ac.uk 
SIGN develops evidence based 
clinical practice guidelines for the 
National Health Service (NHS) in 
Scotland [9]. 
[To improve the quality of health 
care for patients in Scotland 
 by reducing variation in 
practice and outcome] 
 through the development and 
dissemination of national 
clinical guidelines containing 
recommendations for effective 
practice based on current 
evidence 
SIGN makes a “considered 
judgment” 
Membership, currently 39,  
comprised of all the medical specialties 
 Nursing 
 Pharmacy 
 Dentistry 
 Professions allied to medicine 
 Patients 
 Health service managers 
 Social services 
 Researchers 
List of members available online 
 Quality of evidence for guidelines: 
 Volume of evidence 
 Applicability 
 Generalisability 
 Consistency 
 Clinical impact 
 Resource implications 
 Other factors (open category) 
 Recommendations 
 Potential harms associated with 
implementation of a 
recommendation 
 Whether, and to what extent, 
any equality groups may be 
particularly advantaged or 
disadvantaged by the 
recommendations made 
 Implementability, i.e. how 
practical it would be to implement 
the recommendation) 
 Difference of opinion recorded and 
reason for dissent noted 
 Peer review process evaluates clarity 
of guideline recommendations and 
usefulness as working tool 
 „National Open Meeting“: widely 
publicized, 150-300 participants – 
draft guidelines available online 
prior for 1 month 
 Comments documented: each point 
addressed, resulting changes noted, 
if no change made, reasons recorded 
 Pilot testing of guidelines as part of 
local implementation process instead 
of in one isolated pilot site, as 
feasibility of implementation in one 
environment may not be applicable 
to another 
CAN 
Ontario 
Ontario 
Health 
Technology 
Advisory 
Committee 
OHTAC 
www.hqontario.
ca 
 To review, investigate, and 
advise on the uptake, diffusion, 
and distribution of new health 
technologies and the 
replacement and/or removal  
of obsolete or old health 
technologies [10] 
 It makes recommendations to 
the Health Quality Ontario 
Board on the best evidence 
about the best health care 
services and medical devices 
 
 
 
 
Board of Health Quality Ontario HQO 
appoints members for renewable 2-year 
terms 
Chair and Vice-Chair serve for a 
maximum of 5 years 
12 members minimum, 30 maximum 
(currently 28) 
 Representatives from hospital, 
community and long-term care sectors 
 Nursing and medical professions 
 Ontario Hospital Association 
 Ontario Medical Association 
 Council of Academic Hospitals of 
Ontario 
 Local Health Integration Networks 
4 appraisal decision criteria and  
9 sub-criteria [11], see Appendix 
 10 meetings a year 
 OHTAC creates and implements 
mechanisms to involve general public  
 OHTAC invites public engagement in 
reaching recommendations 
 Decisions by consensus 
 If not possible: simple majority of 
members present (significant 
objections noted) 
 OHTAC tracks and reports on the 
implementation of recommendations 
 Diffusion of technology in the 
health care system 
 Performance of the technology 
once diffused 
 Impact on the health care system 
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Country 
Organization/ 
Source of 
Information 
Remit/ 
Terms of Reference Composition Appraisal Criteria Process 
 Board then takes its advice 
into account when formulating 
its recommendations to health 
care organizations and to other 
entities regarding standards of 
care, and to the minister 
regarding the funding, for 
health care services and 
medical devices 
 Ministry of Health and Long-Term 
Care 
 Human factors engineers 
 Academia (health economics, ethics, 
and technology assessment) 
 Industry 
List of members available online 
 OHTAC conducts periodic objective 
evaluations of its work 
 Assuring ongoing relevance 
 Quality 
 Improving overall performance 
 Results of this evaluation are made 
public 
 Members are not to engage in any 
activity or provide any service to any 
other persons or organizations where 
such service creates an actual, 
potential, or perceived conflict of 
interest without prior written 
consent of the Chair 
CAN 
Quebec 
Policy 
Committee of 
McGill 
University 
Health Centre 
– Technology 
Assessment 
Unit 
www.mcgill.ca/
tau/ 
Advises the hospital in difficult 
resource allocation decisions, 
using an approach based on 
sound, scientific technology 
assessments and a transparent, 
fair decision-making process. 
Members (currently 11) chosen by  
their peers 
 Nurses 
 Allied health-care workers 
 Patients 
 Administrators 
 Doctors 
List of members available online 
n/a Local involvement: committee is supple-
mented for each report by representatives 
of discipline most affected 
 They provide subject expertise 
 They greatly influence acceptance 
Transparency: Policy recommendations 
distributed together with the data and 
the reasoning behind them 
Communication: reports and policy 
recommendations 
 Submitted to the hospital authorities 
 Made public to the hospital 
community 
 Made available to organizations and 
hospitals for which the topic might 
be relevant 
 Posted on the TAU website 
Evaluation: regular follow-up of each 
policy recommendation to document 
impact on hospital policy 
NL National 
Health Care 
Institute –
Zorginstituut 
Nederland 
www.zorginstitu
utnederland.nl 
 
 Advises board of directors on 
societal implications 
 Appraisal Committee laid 
down by national law 
Appraisal Committee 9 members 
 3 members from the board of directors 
 6 appointed by minister of health 
with expertise in 
 HTA 
 Medical ethics 
 Medical practice and decision 
making 
 Necessity 
 Efficacy 
 Cost-effectiveness 
 Feasibility 
 Open to public and press 
 Agenda published online 
 Stakeholders are given the opportunity 
to briefly state their case, provided 
they have requested to do so in 
advance 
 Decisions normally by consensus of 
members present 
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Country 
Organization/ 
Source of 
Information 
Remit/ 
Terms of Reference Composition Appraisal Criteria Process 
http://bit.ly/1
CVlVfl  
 Long term care 
 Patient‘s perspective 
List of members and conflict of interest 
statements available online: 
http://bit.ly/1tAYP79 (in Dutch) 
 Operated in tandem with „Assessment 
Committee“ (evidence issues) 
USA United States 
Preventive 
Services Task 
Force – USPSTF 
www.usprevent
iveservicestask
force.org 
 Conducts scientific evidence 
reviews of a broad range of 
clinical preventive health care 
services (such as screening, 
counseling, and preventive 
medications) [12] 
 Develops recommendations 
for primary care clinicians and 
health systems 
 Strives to make accurate,  
up-to-date, and relevant recom-
mendations about preventive 
services in primary care 
„Assessing evidence is job of Task 
Force“ 
 Up to 16 members (currently 16) 
 Members from fields of preventive 
medicine, evidence-based medicine 
and primary care 
 Internal medicine 
 Family medicine 
 Pediatrics 
 Behavioral health 
 Obstetrics and gynecology 
 Nursing 
Online form to nominate members 
List of members available online 
 Health benefits and harms are the 
outcomes that matter most in 
weighing the evidence and making 
recommendations 
 Economic costs (direct and 
indirect), both to individuals and 
to society, warrant consideration 
in making recommendations but 
are not the first priority 
 Feasibility and public expectations 
may take precedence over narrower 
scientific evidence in clinical practice 
and in public policy 
 Preliminary recommendations 
posted online for public comment 
for 4 weeks 
 Final recommendation statements 
include “Response to Public 
Comments” section, summarizing 
how the Task Force addressed 
comments received 
AUS National 
Health and 
Medical 
Research 
Council – 
NHMRC 
www.nhmrc. 
gov.au 
 Statutory responsibilities to 
 [raise the standard of 
individual and public health 
throughout Australia] 
 foster the development of 
consistent health standards 
[13] 
 It encourages the development 
of evidence-based guidelines 
and its duties include 
approving guidelines 
 Brings together within a single 
national organization the 
functions of research funding 
and development of advice 
  [CEO is directly responsible to 
the Minister for Health and 
Minister for Sport] 
Members of the Council 
 Part-time appointees 
 Appointment up to 3 years 
 Reappointment possible 
Composition of Council (currently 23): 
 Chair 
 Chief medical officer for the 
Commonwealth 
 Chief medical officer for each State 
and Territory 
 Person with expertise in the health 
needs of Aboriginal persons and 
Torres Strait Islanders 
 Person with expertise in consumer 
issues 
 Person with expertise in business 
 At least 6, but no more than 11, 
persons with expertise in one or 
more of the following: 
 Health care training 
 Professional medical standards 
 
n/a  Council meets in full session on 
several occasions each year 
 Proceedings of each session made 
available online 
Guideline development 
 Public consultation required 
 30 days 
 Notice published in at least 1 
major national daily newspaper 
 Use of socio-economic evidence 
focusing on differences mandated 
 After 5 years: recommendation to 
NHMRC's CEO if guidelines need to 
be reviewed 
 After 10 years: all guidelines either 
reviewed and evidence updated, or 
revoked 
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Country 
Organization/ 
Source of 
Information 
Remit/ 
Terms of Reference Composition Appraisal Criteria Process 
 Medical profession and post 
graduate medical training 
 Nursing profession 
 Public health research and 
medical research issues 
 Public health 
 Ethics relating to research 
involving humans 
List of members available online 
CH Swiss Federal 
Services Policy 
Commission – 
Eidgenoessische 
Leistungs- und 
Grundsatz-
kommission 
ELGK 
at the Federal 
Office of Public 
Health – 
Bundesamt für 
Gesundheit 
BAG 
www.bag.admin
.ch 
Recommends for or against 
coverage by social health 
insurance 
 Currently 18 members 
 Nominated by government 
(Bundesrat) 
List of interests/institutional ties 
(Interessensbindungen) of each 
member available online 
List of members available online 
Effectiveness (Wirksamkeit) 
operationalized as [14]: 
 Are reproducible studies on 
effectiveness available? 
 What is their quality? 
 Are the results relevant outcomes? 
 Are the results of multiple studies 
consistent? 
 Are the results transferable to 
Switzerland? 
Appropriateness (Zweckmäßigkeit) 
operationalized as [14]: 
 Relevant/necessary 
 Net benefit in relation to 
comparator(s) 
 Is there a more cost effective 
alternative? 
 Is there risk of inappropriate 
utilization? 
Economic (Wirtschaftlichkeit) 
operationalized as [14]: 
 Economical (cost-effectiveness) 
 Plausibility of cost and price 
calculation 
 Cost impact 
Appraisal check-list under development 
Proceedings and minutes are 
confidential 
Process in case of conflict of interests 
detailed 
Positive recommendations often 
include restrictions 
 Particular patient group 
 Particular service provider 
 Provisional limited funding pending 
evaluation 
Negative recommendations include 
justification 
No appeal possible 
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15 
Country 
Organization/ 
Source of 
Information 
Remit/ 
Terms of Reference Composition Appraisal Criteria Process 
GER Federal Joint 
Committee – 
Gemeinsamer 
Bundes-
ausschuss 
G-BA 
www.g-ba.de 
 [Is the highest decision-making 
body of the joint self-
government of physicians, 
dentists, hospitals and health 
insurance funds] 
 Issues directives for the benefit 
catalogue of the statutory 
health insurance funds and 
thus specifies which services in 
medical care are reimbursed 
 Subcommittee 
(themenbezogene 
Arbeitsgruppe) appraises 
evidence gathered during 
external assessment 
 [Specifies measures for quality 
assurance in inpatient and 
outpatient areas] 
Appointment for 6 year term 
13 (voting) members 
 1 impartial chair and 2 impartial 
members (salaried) 
 5 members appointed by National 
Association of Health Insurance Funds 
 2 members appointed by German 
Hospital Federation 
 2 members appointed by National 
Association of Statutory Health 
Insurance Physicians 
 1 member appointed by National 
Association of Statutory Health 
Insurance Dentists 
These patient and self-help organizations 
are currently entitled to appoint  
(non-voting) patient representatives: 
 German Council of People with 
Disabilities 
 Federal Syndicate of Patient Interest 
Groups 
 German Syndicate of Self-Help Groups 
 Federation of German Consumer 
Organizations 
List of members available online 
 Benefit 
 Necessity 
 Cost-effectiveness 
in light of care for insured population 
that is sufficient (ausreichend), 
appropriate (zweckmäßig) and 
economic (wirtschaftlich) 
These criteria are further detailed in 
the rules of procedure 
(Verfahrensordnung): www.g-ba.de/ 
informationen/richtlinien/42  
 Detailed rules of procedures 
available online [15] 
 The plenary assembly meets once or 
twice a month in public session. Sub-
committee meetings are not open to 
the public. 
 Plenary assembly resolution passed if 
at least 7 votes in favor 
 Subcommittee (themenbezogene 
Arbeitsgruppe) appraises evidence 
gathered during external assessment 
1. Subcommittee determines in a first 
step the patient-relevant benefit of 
technology as compared to the 
current standard (independent of 
intra- or extramural delivery of 
service) 
2. Subcommittee determines in a 
second step if the technology is to 
be provided in the intramural sector 
only or in the extramural sector as 
well, whether there are sufficient 
qualified service providers etc. 
 Hearing required when interests of 
third parties affected 
 Results of hearing evaluated by 
subcommittee 
 Detailed final report summarizing 
proceedings and content of 
consultations accessible online 
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3 A (good) practice example: Ontario’s OHTAC 
Ontario is Canada’s most populous province with almost 13 Mio. inhabitants. 
In 2003 Ontario started to develop a single provincial portal for the uptake 
and diffusion of health technologies based on an approach that is evidentiary, 
bottom-up, transparent, accountable and open to appeal [2]. The figure be-
low illustrates Health Quality Ontario’s (HQO) Evidence Review Process. 
 
Figure 2: Ontario Evidence Review Process. Source: [16] 
Abbreviations: HQO ... Health Quality Ontario,  
OHTAC ... Ontario Health Technology Advisory Committee 
Based on the available evidence the Ontario Health Technology Advisory 
Committee (OHTAC) – a standing advisory committee appointed by HQO’s 
Board – makes recommendations about the uptake, diffusion, distribution or 
removal of health interventions. Its members include representatives from the 
hospital, community and long-term care sector, nursing and medical profes-
sions, Ontario Hospital Association, Ontario Medical Association, Council of 
Academic Hospitals of Ontario, Local Health Integration Networks, Ministry 
of Health and Long-Term Care, academia (health economics, ethics and tech-
nology assessment) and industry. A list of OHTAC’s current members is avail-
able online. OHTAC considers existing clinical practice, economic issues, 
human resource issues, societal values, regulatory implications and ethical 
issues in its recommendations. OHTAC’s Decision Determinants Subcommit-
tee currently develops a decision determinants framework that considers the 
clinical benefit offered by a health intervention in addition to value for money, 
societal and ethical considerations and economic and organizational feasibil-
ity. OHTAC facilitates broad stakeholder engagement via its professional and 
public consultation process, in which its recommendations are open for com- 
 
Health Quality Ontario 
(HQO) Evidence Review 
Process: transparent 
from assessment to 
appraisal to decision 
multi-step process: 
step 1: framing the 
policy questions 
step 2: HTA 
step 3: recommendations 
by HTA 
step 4: appraisal + 
recommendations 
step 5: processing of 
appraisal 
recommendations 
step 6: publication of 
results 
step 7: possible need for 
further evidence 
generation or piloting 
appraisal committee of 
OHTAC contextualizes 
evidence based on:  
 
current clinical practice, 
cost-benefit aspects 
(= clinical benefit and 
value for money), 
organizational 
feasibility + usability, 
human resources, 
acceptance, 
societal values, 
ethical implications 
A (good) practice example: Ontario’s OHTAC 
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ment for 21 days. Using OHTAC’s recommendations and advice, the Health 
Quality Ontario Board formulates final recommendations to the health care 
system and the Minister of Health and Long-Term Care [10]. 
Common recommendations include increasing funding or access to an inter-
vention, recommending against the use of an intervention in Ontario or rec-
ommending access to an intervention for only certain patient groups or clin-
ical indications. When there is insufficient evidence on the safety, effective-
ness and/or cost-effectiveness of a health intervention, a field evaluation may 
be recommended and commissioned. The value of these evaluations strongly 
depends on the study design. Thereby Ontario funds and evaluates promising 
health interventions in real-time clinical settings. The program is designed to 
inform policy and funding decisions prior to making long-term commitments 
and is the largest of its kind in the world. It represents a conditional funding 
model for promising technologies. Field evaluation partners are research in-
stitutes focused on multi-centered clinical trials and economic evaluation, as 
well as institutes engaged in evaluating the safety and usability of health tech-
nologies [3, 10]. 
Ontario’s evidence review process has changed the way policy makers view 
and use health technology analyses. Instead of the traditional static report that 
does not address the needs of decision makers the Ontario process is more 
relevant, responsive and dynamic [3]. 
 
 
 
 
recommendations 
include: 
increasing funding or 
access to intervention; 
no funding; 
disinvestment; 
limitation to specific 
patient groups 
 
field evaluation  
and piloting under 
conditional coverage 
transition from 
traditional static HTA 
reports to dynamic 
responses to policy 
questions 
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4 Recommendations for appraisal committees 
HTA has the potential to form an integral part of a comprehensive continu-
um for evidence-informed decision making. This process requires transpar-
ency and inclusiveness [2]. Recommendations stemming from an appraisal 
process that are well supported by good evidence and clear reasoning can carry 
considerable weight. Making them public makes it even harder for decision 
makers not to consider them [1]. In case a recommendation departs from 
available evidence, clear arguments for this deviation have to be put forth. 
This is a departure from traditional ways in which policy decisions are made 
by administrators behind closed doors [1]. Realistically, what is necessary to 
achieve the translation from evidence to policy deployment, is a mosaic of 
programs [2]. Appraisal committees informed by good practice are one such 
mosaic stone. This final chapter suggests seven recommendations to consider 
when establishing an appraisal committee. These recommendations are drawn 
from the international experience presented in the chapters above. 
1. The remit of the appraisal committee should be clearly stated. It should 
not only address new technologies but also encompass the evaluation 
of existing ones in view of disinvestment decisions (e.g. Switzerland’s 
ELGK). The appraisal committee’s terms of reference should also in-
clude scoping of issues, follow-up evaluation of a technology (e.g. Can-
ada’s OHTAC monitors the diffusion of the technology in the health 
care system, its performance once diffused and its impact on the health 
care system) and the periodic update of recommendations (e.g. Aus-
tralia’s NHMRC). 
2. The procedural rules governing the appraisal committee’s work should 
be documented and available to the general public (e.g. UK’s NICE, 
Germany’s G-BA). These should include the set of criteria used for the 
appraisal, ideally operationalized (e.g. UK’s NSC). Information on 
whether and how criteria are weighed against each other is desirable 
but not yet found in practice.  
3. Committee membership should encompass as diverse a set of back-
grounds as possible to accurately represent the public in the interest 
of which a decision is recommended. The list of professions and areas 
of public life to be represented by committee members and the list of 
the actual nominated members should be available to the public (as is 
standard at all presented regional or national committees) alongside re-
gulations on conflict of interest (e.g. UK’s NICE, Switzerland’s ELGK) 
and individual member’s declarations. To offer the public the chance 
to suggest new members (e.g. United States PSTF) adds to the open-
ness of the process. Rules for possible re-appointment (e.g. Australia’s 
NHMRC) and a limit for the total period of appointment (e.g. Ger-
many’s G-BA or Canada’s OHTAC for Chair and Vice-Chair) are rec-
ommended. 
4. Meeting agendas should be publicly advertised well in advance. The 
committee deliberations should allow, where possible, for at least par-
tial openness to the public (e.g. UK’s NICE). When reaching recom-
mendations, difference of opinion between committee members should 
be documented and reasons for dissent noted (e.g. Scotland’s SIGN). 
Minutes should be published online alongside the recommendations 
(e.g. Canada’s OHTAC). 
HTA as part of  
evidence-informed 
decision making: 
process requires 
transparency and 
inclusiveness 
 
appraisal committees are 
essential mosaic stone in 
evidence-informed 
decision making 
clearly stated remit: 
decision support ... 
 
... on investment and 
disinvestment 
documented procedural 
rules incl. appraisal 
criteria available to  
the public 
diverse set of 
backgrounds for 
membership 
to accurately represent 
the public 
 
conflict of interest 
policy 
 
rules for  
re-appointments and 
maximum terms 
documentation of 
arguments for/against 
recommendations,  
of dissent and  
of reasons for deviation 
from evidence 
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5. Public (e.g. UK’s NICE) or stakeholder consultations (e.g. Germany’s 
G-BA, the Netherland’s National Health Care Institute) should be an 
integral part of the process, preferably both in the prior HTA evidence 
assessment and in the committee’s appraisal. Stakeholder consulta-
tions should be considered as additional input used by the appraisal 
committee when formulating its recommendation, but does not replace 
the function of the appraisal committee itself. The formats of public 
outreach should be variable and appropriate for the respective rele-
vant target group (e.g. UK’s NSC or Scotland’s SIGN). Comments 
should be documented, each point addressed, resulting changes noted 
and if no change ensues, reasons should be recorded (e.g. Scotland’s 
SIGN). It should be clearly defined who qualifies as stakeholder in a 
specific technology deliberation (e.g. UK’s NSC). 
6. Earmarked funding should make additional evidence collection through 
pilot testing, trials etc. possible, if needed (e.g. Canada’s OHTAC, the 
Netherland’s National Health Care Institute’s coverage within the Evi-
cence Development Program). 
7. A process to appeal a recommendation may be made available (e.g. 
UK’s NICE). The addressee of the recommendations, e.g. the federal 
health minister, should officially have to react to them to increase ac-
countability (e.g. in the Netherland when the Health Council is con-
sulted). Tracking and reporting on implementation of recommenda-
tions should be an integral part of the appraisal process (e.g. Canada’s 
OHTAC). Finally a periodic evaluation of the impact of the appraisal 
committee’s work (e.g. Canada’s OHTAC) should be envisioned. 
 
 
clear definition who 
qualifies as stakeholder  
 
public involvement: 
public outreach 
appropriate for relevant 
target group, 
documentation of 
comments  
earmarked funding for 
additional evidence 
generation if needed 
process of appeal may 
be considered, 
tracking and reporting 
on implementation of 
recommendations, 
evaluation of impact of 
the appraisal 
committee’s work 
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5 Appendix: Examples of detailed appraisal criteria 
In the previous chapter recommendation 2 for good-practice in appraisal committees prescribes the for-
mulation of a set of criteria used for the appraisal. To illustrate this, a detailed example from the UK 
and one from Canada are presented in this appendix. 
 
 
5.1 UK National Screening Committee 
The UK National Screening Committee employs 22 criteria for appraising the viability, effectiveness 
and appropriateness of a screening program [8]. Ideally all the following criteria should be met before 
screening for a condition is initiated. 
 
 No. Criteria 
The 
Condition 
1. The condition should be an important health problem 
2. The epidemiology and natural history of the condition, including development from 
latent to declared disease, should be adequately understood and there should be a 
detectable risk factor, disease marker, latent period or early symptomatic stage. 
3. All the cost-effective primary prevention interventions should have been implemented 
as far as practicable. 
4. If the carriers of a mutation are identified as a result of screening the natural history of 
people with this status should be understood, including the psychological implications. 
The 
Test 
5. There should be a simple, safe, precise and validated screening test. 
6. The distribution of test values in the target population should be known and a suitable 
cut-off level defined and agreed. 
7. The test should be acceptable to the population. 
8. There should be an agreed policy on the further diagnostic investigation of individuals 
with a positive test result and on the choices available to those individuals. 
9. If the test is for mutations the criteria used to select the subset of mutations to be covered 
by screening, if all possible mutations are not being tested, should be clearly set out. 
The 
Treatment 
10. There should be an effective treatment or intervention for patients identified through 
early detection, with evidence of early treatment leading to better outcomes than late 
treatment. 
11. There should be agreed evidence based policies covering which individuals should be 
offered treatment and the appropriate treatment to be offered. 
12. Clinical management of the condition and patient outcomes should be optimized in all 
health care providers prior to participation in a screening programme. 
The 
Screening 
Programme 
13. There should be evidence from high quality Randomized Controlled Trials that the 
screening programme is effective in reducing mortality or morbidity. Where screening 
is aimed solely at providing information to allow the person being screened to make an 
“informed choice” (e.g. Down’s syndrome, cystic fibrosis carrier screening), there must 
be evidence from high quality trials that the test accurately measures risk.  
The information that is provided about the test and its outcome must be of value and 
readily understood by the individual being screened. 
14. There should be evidence that the complete screening programme (test, diagnostic 
procedures, treatment/intervention) is clinically, socially and ethically acceptable to 
health professionals and the public. 
15. The benefit from the screening programme should outweigh the physical and 
psychological harm (caused by the test, diagnostic procedures and treatment). 
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 No. Criteria 
The 
Screening 
Programme 
(continued) 
16. The opportunity cost of the screening programme (including testing, diagnosis and 
treatment, administration, training and quality assurance) should be economically 
balanced in relation to expenditure on medical care as a whole (i.e. value for money). 
Assessment against this criteria should have regard to evidence from cost benefit and/or 
cost effectiveness analyses and have regard to the effective use of available resource. 
17. All other options for managing the condition should have been considered  
(e.g. improving treatment, providing other services), to ensure that no more cost 
effective intervention could be introduced or current interventions increased within 
the resources available. 
18. There should be a plan for managing and monitoring the screening programme and  
an agreed set of quality assurance standards. 
19. Adequate staffing and facilities for testing, diagnosis, treatment and programme 
management should be available prior to the commencement of the screening 
programme. 
20. Evidence-based information, explaining the consequences of testing, investigation and 
treatment, should be made available to potential participants to assist them in making 
an informed choice. 
21. Public pressure for widening the eligibility criteria for reducing the screening interval, 
and for increasing the sensitivity of the testing process, should be anticipated. 
Decisions about these parameters should be scientifically justifiable to the public. 
22. If screening is for a mutation the programme should be acceptable to people identified 
as carriers and to other family members. 
 
 
5.2 Ontario Health Technology Advisory Committee 
Ontario Health Technology Advisory Committee recommendations are guided by a decision determinants 
framework [11], that considers the clinical benefit offered by a health intervention, in addition to value 
for money, societal and ethical considerations; and economic and organizational feasibility. It encom-
passes the 4 decision criteria and 9 sub-criteria below. The framework is currently being reviewed and 
updated by the Decision Determinants Subcommittee. 
 
No. Decision Criteria No. Sub-Criteria 
1. Overall clinical benefit 1. Effectiveness 
2. Safety 
3. Burden of illness 
4. Need 
2. Consistency with expected societal and ethical values 5. Expected Societal values 
6. Expected Ethical values 
3. Value for Money 7. Economic evaluation 
4. Feasibility of adoption into health system 8. Economic feasibility 
9. Organizational feasibility 
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